Modulation of inflammation by autophagy: Consequences for human disease

Romana T. Netea-Maier, Theo S. Plantinga, Frank L. van de Veerdonk, Johannes W. Smit & Mihai G. Netea

To cite this article: Romana T. Netea-Maier, Theo S. Plantinga, Frank L. van de Veerdonk, Johannes W. Smit & Mihai G. Netea (2016) Modulation of inflammation by autophagy: Consequences for human disease, Autophagy, 12:2, 245-260, DOI: 10.1080/15548627.2015.1071759

To link to this article: https://doi.org/10.1080/15548627.2015.1071759

© 2016 The Author(s). Published with license by Taylor & Francis.© Romana T. Netea-Maier, Theo S. Plantinga, Frank L. van de Veerdonk, Johannes W. Smit, and Mihai G. Netea.

Accepted author version posted online: 29 Jul 2015. Published online: 26 Jan 2016.

Submit your article to this journal

Article views: 4547

View related articles

View Crossmark data

Citing articles: 103 View citing articles
Modulation of inflammation by autophagy: Consequences for human disease

Romana T. Netea-Maier¹², Theo S. Plantinga⁳, Frank L. van de Veerdonk⁴⁵, Johannes W. Smit⁴⁵, and Mihai G. Netea⁴⁵

¹Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; ²Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands; ³Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands

ABSTRACT
Autophagy and inflammation are 2 fundamental biological processes involved in both physiological and pathological conditions. Through its crucial role in maintaining cellular homeostasis, autophagy is involved in modulation of cell metabolism, cell survival, and host defense. Defective autophagy is associated with pathological conditions such as cancer, autoimmune disease, neurodegenerative disease, and senescence. Inflammation represents a crucial line of defense against microorganisms and other pathogens, and there is increasing evidence that autophagy has important effects on the induction and modulation of the inflammatory reaction; understanding the balance between these 2 processes may point to important possibilities for therapeutic targeting. This review focuses on the crosstalk between autophagy and inflammation as an emerging field with major implications for understanding the host defense on the one hand, and for the pathogenesis and treatment of immune-mediated diseases on the other hand.

Introduction
Autophagy is the physiological cellular process through which intracellular components undergo lysosome-mediated self-digestion and recycling.¹ In conditions of cellular stress such as starvation, hypoxia, or exposure to toxic molecules, the autophagy machinery is activated in order to maintain cell homeostasis. An increasing body of evidence has emerged supporting the view that autophagy is involved in several physiological processes including cell metabolism, cell survival, and host defense.² It can be argued that autophagy is a primordial form of eukaryotic innate immunity against invading microorganisms. Research performed in the past decade has also proposed that, in mammals, these primordial functions of autophagy have evolved and now encompass multiple innate and adaptive immune mechanisms.³ Moreover, defective autophagy is associated with several pathological conditions such as cancer, autoimmune disease, neurodegenerative disease, and senescence.⁴ These new insights strongly suggest that besides its classical role as a “housekeeping” mechanism, autophagy can also be considered as crucial for host defense in general, and regulation of inflammation in particular. In this review we present the newest concepts that link these 2 fundamental biological processes, autophagy, and inflammation.

Autophagy and host defense
Several types of autophagy have been recognized, including macroautophagy, microautophagy, chaperone-mediated autophagy, and noncanonical autophagy.⁵ In this review we will focus on macroautophagy, which will be henceforth referred to as autophagy. This process is activated in response to a multitude of stress factors including starvation, hypoxia, and other toxins that result in accumulation of damaged organelles and protein aggregates. As a consequence, a double-layer membrane, the phagophore, is formed to engulf the damaged cytosolic components (Fig. 1). After complete sequestration of these components, the resulting autophagosome fuses with the lysosome, which enables the breakdown of the autophagosome inner membrane and exposes the cargo to the lysosomal hydrolases. The resulting breakdown products are subsequently released in the cytosol and are available to be reused for the synthesis of required macromolecules.⁶ Several autophagy-related (ATG) genes and proteins are involved in the induction of autophagy (Fig. 1), while a subset of them also have autophagy-independent functions.⁶

Among the most important functions of autophagy in addition to maintaining cell homeostasis is its role in host defense. Autophagy improves host defense mechanisms through several biological functions: the direct elimination of the invading pathogens (involving also xenophagy and MAP1LC3/LC3 [microtubule-associated protein 1 light chain 3]-associated phagocytosis-LAP),⁶ control of adaptive immunity through regulation of antigen handling and presentation,⁸,⁹ induction of innate immune memory or trained immunity,¹⁰ and modulation of inflammation. Indeed, autophagy has been suggested to represent an ancient form of innate immune response to an infection.¹¹ Engagement of various families of pattern-recognition receptors (PRRs) has been reported to induce autophagy through pathways that are similar to those activated in response to nutrient deprivation, and mediated via mTOR (mechanistic target of rapamycin [serine/threonine kinase]) and adenosine...
monophosphate (AMP)-activated protein kinase (AMPK). In this respect, engagement of TLR4 (toll-like receptor 4) by lipopolysaccharide (LPS) of Gram-negative bacteria results in the ubiquitination of BECN1/beclin-1 by TRAF6 (TNF receptor-associated factor 6, E3 ubiquitin protein ligase). TRAF6 also activates the serine/threonine protein kinase ULK1 (unc-51 like autophagy activating kinase 1), both pathways leading to the activation of autophagy. Interestingly, the LPS-induced autophagy is dependent on MAPK/p38 and TICAM1/TRIF (toll-like receptor adaptor molecule 1), but not on MYD88 (myeloid differentiation primary response 88). Similarly, the engagement of several other TLRs also induces autophagy. Not only TLRs, but nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) as well have been demonstrated to induce autophagy: NOD2 induces autophagy in dendritic cells and directs antigen handling and presentation, a process that involves targeting of ATG16L1 to the plasma membrane at the site of bacterial entry.

In addition to PRRs, several proinflammatory cytokines including TNF (tumor necrosis factor) and IL1B (interleukin 1, β) induce autophagy and thus improve the control of infection. Furthermore, both type I (IFNA/IFNα-IFNB1/IFNβ-IL6) and type II (IFNG/IFNγ) interferons are major factors in activating autophagy. For instance, activation of macrophages by IFNγ is crucial for intracellular killing of Mycobacterium tuberculosis, and type I IFN for host defense against viruses. In mice, IFNG induces the expression of autophagic p47 immunity-related guanosine-5’-triphosphate (GTP)ases (IRG) proteins, with IRGM1 (immunity-related GTPase family M member 1) being an important factor for inducing antmycobacterial autophagy. These findings are corroborated by the genetic association of IRGM polymorphisms with tuberculosis in West Africans, and increased Bacillus Calmette-Guérin (BCG) vaccination efficacy through enhanced antigen presentation.

In contrast to the proinflammatory cytokines, T helper 2 (Th2) type responses and secretion of anti-inflammatory cytokines such as IL4 and IL13 antagonize autophagy induction through activation of MTOR. Altogether, the T helper 1/T helper 2 (Th1/Th2) responses seem to be correlated to the activation of autophagy, with autophagy being induced in Th1 type responses and inhibited when Th2 responses are elicited.

In addition, it must be underlined that some infectious agents are able to manipulate and inhibit autophagy, a de facto mechanism of evasion from the host defense. In line with this, human immunodeficiency virus (HIV) infection of CD4 lymphocytes reduces their content of BECN1 and MAP1LC3B-II, crucial components for the induction of autophagy.

The impact of autophagy on inflammation

Innate immunity represents the first line of defense against pathogens. It requires adequate pathogen recognition, which triggers activation of inflammation resulting in recruitment of immune cells, such as phagocytes, secretion of cytokines and

![Figure 1. The process of autophagy in eukaryotic cells and its involvement in cellular homeostasis, metabolism, and the immune system. Autophagy is induced both by metabolic and immune signals comprising pathogen recognition and stimulation by proinflammatory cytokines. Upon autophagy triggering through any of these pathways, the MAP1LC3B (depicted as unconjugated LC3B-I and PE-conjugated LC3B-II) and ATG12 conjugation systems, as well as BECN1 and class III PtdIns3K, are activated that are critical for autophagosome formation. After engulfment of the autophagic cargo, autophagosomes proceed to lysosomal fusion, leading to degradation of the sequestered content. In case the autophagic cargo originates from intracellular organelles or protein complexes, the degraded fragments are utilized for metabolic purposes to generate ATP and provide the cell with free amino acids. In contrast, autophagy-mediated degradation of extracellular material, especially microbes, enables pathogen killing and activation of adaptive immunity by MHC-dependent antigen presentation.](image-url)
chemokines, which in turn help recruit other immune cells and prime dendritic cells (DCs) for activation of adaptive immune responses. An increasing number of studies have recently shown that autophagy has important effects on the induction of the inflammatory reaction. However, when the inflammatory process is not properly controlled, autophagy can be detrimental for the host. In atherosclerosis, excessively stimulated autophagy can lead to endothelial cell death that can contribute to plaque destabilization, maintaining the inflammatory status of the plaque. In chronic obstructive pulmonary disease (COPD) cigarette smoking triggers a form of autophagy, namely mitophagy (autophagy-dependent selective elimination of mitochondria), through stabilization of the mitophagy regulator PINK1 (PTEN-induced putative kinase 1). This eventually leads to epithelial cell death, and thus can contribute to persisting inflammatory responses in COPD.

**Autophagy effects on inflammasome activation and IL1B production**

Production of cytokines from the IL1 family, and especially IL1B, is one of the main mechanisms through which innate and adaptive immune responses are induced by an infection. The regulation of the production of this cytokine is thus crucial for understanding inflammation and host defense. Probably the best studied aspect of the interaction between autophagy and inflammation is represented by the effects of autophagy on inflammasome activation and IL1B release. An overview of the interplay between autophagy and IL1B-inflammasome activation is depicted in Figure 2. The inflammasome consists of protein complexes formed by one or more members of the NLR family of receptors together with CASP1/caspase-1, leading to the activation of this cysteine protease, and processing of the inactive pro-IL1B and pro-IL18 into active cytokines. The activation of this cysteine protease, and processing of the family of receptors together with CASP1/caspase-1, leading to inflammation is represented by the effects of autophagy on inflammasome activation and IL1B release. An overview of the interplay between autophagy and IL1B-inflammasome activation is depicted in Figure 2. The inflammasome consists of protein complexes formed by one or more members of the NLR family of receptors together with CASP1/caspase-1, leading to the activation of this cysteine protease, and processing of the inactive pro-IL1B and pro-IL18 into active cytokines. The first observation regarding the effect of autophagy on inflammasome activation was that of Saitoh et al. who reported that macrophages of Atg16l1 knockout mice respond with increased production of IL1B after stimulation with LPS. This was due to an exaggerated activation of CASP1 in the Atg16l1-deficient mice, mediated by the adapter molecule TICAM. Additional studies support the concept that autophagy regulates inflammasome activation. Several mechanisms have been proposed to mediate these anti-inflammatory effects of autophagy. During homeostatic conditions autophagy is responsible for the clearing of the cytoplasm of nonfunctional mitochondria and other organelles. If autophagy is defective this leads to an accumulation of depolarized mitochondria, that release inflammasome activators such as reactive oxygen species (ROS) or mitochondrial DNA (mtDNA). Moreover, autophagy may also remove aggregated inflammasome structures, thus contributing to dampening proinflammatory responses. These processes might play an important role during infections. This is underscored by the observation that influenza virus triggers RIPK2 (receptor-interacting serine-threonine kinase 2) to activate ULK1, to enhance mitophagy and control inflammasome activation. These studies in mice point toward a regulatory effect of autophagy on CASP1 activation through modulation of the NLRP3 (NLR family, pyrin domain containing 3) inflammasome.

The important role of autophagy for IL1B secretion was also confirmed in human primary cells, in which inhibition of autophagy leads to increased production of IL1B. Interestingly, the same study in humans demonstrated that TNF production is decreased by autophagy inhibition, suggesting divergent effects of autophagy on the production of these cytokines. However, important differences may exist between mice and humans regarding the effect of autophagy on IL1B production. In mice, this effect is ascribed to inhibition of inflammasome activation by autophagy, whereas in humans IL1B mRNA transcription is elevated when autophagy is inhibited, whereas no effects are observed on CASP1 activation. One potential mechanism for this observation was proposed to be due to targeting pro-IL1B for degradation, while a recent study also reported autophagy-dependent degradation of the PELI (pellino 3 ubiquitin ligase) with subsequent inhibition of IL1B expression during TLR4 signaling. These discrepancies between mice and humans emphasize that caution should be exercised when extrapolating studies from mice to humans. Moreover, it has recently been demonstrated that a noncanonical secretion pathway controlled by autophagy plays an important role in the secretion of proteins that lack a signal sequence, such as IL1B. In contrast to basal autophagy, which inhibits IL1B secretion, induced autophagy augments IL1B secretion via an unconventional secretion mechanism that utilizes the autophagic machinery.

**The effect of autophagy on other inflammatory pathways**

Autophagy does not only have inhibitory effects on inflammasome activation, but also on inflammatory mediators that are independent of CASP1 activation. In line with this, autophagy suppresses CAPN/calpain-dependent IL1B activation, and this effect is linked to the release of ROS as well. In addition, autophagy reduces NFKB (nuclear factor of kappa light polypeptide gene enhancer in B-cells) activation by selective degradation of BCL10 complexes. This process is mediated through NSFL1C (NSFL1 [p97 cofactor [p47]], a negative regulator of IKBKB/IKK acting via degradation of the polyubiquitinated NFKB modulator IKBKG/NEMO.

In addition to these effects on proinflammatory cytokines, autophagy also amplifies TLR signaling to improve the delivery of microbial ligands to cytoplasmic receptors such as TLR7 that promote the synthesis of type I IFN. This could also lead, however, to inappropriate immune activation, as shown by the increased trafficking of DNA-containing antigens and increased IFNA secretion. However, the effects of autophagy on the stimulation of type I IFN is complex, with the ATG12–ATG5 complex inhibiting the signaling induced by RIG-I-helicase like receptors (RLRs) by direct binding to the caspase-recruitment domain of the RLR adaptor molecule MAVS.

These data suggest therefore that inflammation and autophagy are intertwined processes during host defense, and derangements in the crosstalk between these 2 processes can have important consequences for the pathogenesis and treatment of several diseases.
Autophagy in the pathogenesis and treatment of immune-mediated disease

Due to the mechanisms described above, autophagy has emerged as a central player in the pathogenesis of immune-mediated diseases, including autoinflammatory and autoimmune diseases, infections, and cancer.

The impact of autophagy on autoinflammatory and autoimmune diseases

The first major autoinflammatory disease in which autophagy has been suggested to play a significant role is Crohn disease (CD). CD is a chronic inflammatory disorder of the intestine caused by a combination of multiple factors including defective host response, altered mucosal barrier function, and exaggerated cytokine production. Genetic variants of important autophagy genes such as ATG16L1, IRGM, and ULK1, have been reproducibly associated with susceptibility and clinical outcome of the disease, demonstrating the important role of autophagy in CD. Functional studies have revealed that autophagy and subsequently inflammatory pathways are heavily influenced by genetic variation in autophagy genes, the ATG16L1 variant in particular, as has been demonstrated for defective Paneth cell function, impaired bacterial defense, aberrant antigen presentation, and increased production of proinflammatory cytokines including IL1B and IL18. The IRGM promoter polymorphism risk allele influences IRGM expression, at least in part through posttranscriptional regulation by miRNAs. Furthermore, a well-established genetic risk factor with the highest predictive value for CD is for the gene encoding NOD2, a PRR that recognizes peptidoglycans and activates immune pathways and autophagy. Another indication that autophagy is a central process in intestinal homeostasis is the recent finding of CALCOCO2/NDP52 mutations in CD patients, a gene that codes for an important factor in phagophore targeting of intracellular bacteria.

In addition to CD, important insights have also been provided by the assessment of autophagy induction and inflammasome activation in patients with chronic granulomatous diseases (CGD). CGD is a primary immunodeficiency characterized by defective ROS production due to mutations in the proteins forming the NOX (NADPH oxidase) complex. In addition to the defects in host defense, CGD is characterized by the presence of hyperinflammatory features, such as colitis that is indistinguishable from CD in 30% of the patients. Earlier studies have demonstrated that IL1B production capacity in CGD patients is increased compared to controls, bringing into question the importance of NADPH-dependent ROS production for inflammasome activation. Since NADPH-oxidase dependent ROS production...
was shown to be important for the induction of LAP,\textsuperscript{72,73} this led to the hypothesis that defective LAP in CGD may lead to hyperinflammation. Indeed, a recent study showed defective LAP in both patients with CGD and mice with mutations in genes encoding the NOX complex, which contribute to the exaggerated IL1B production.\textsuperscript{73} More importantly, treatment of CGD patients having colitis with recombinant IL1RN/IL1RA (interleukin 1 receptor antagonist) significantly improve the clinical picture.\textsuperscript{73,74} IL1RN not only reduces excessive IL1- driven inflammation, but also restores deficient LAP in NOX-deficient cells. IL1RN also has intracellular effects, and cellular uptake of IL1RN has been reported.\textsuperscript{75} Therefore, IL1RN might influence LAP through several possible mechanisms: i) direct inhibition of IL1 bioactivity, ii) intracellular interaction with the LAP machinery or iii) indirectly via effects on other processes such as inflammasome activation which is responsible for pro-IL1B processing.

Epidemiological studies assessing genetic variants in autophagy genes demonstrated their association with susceptibility to autoimmune disease as well, such as variants in \textit{ATG5} associated with systemic lupus erythematosus (SLE)\textsuperscript{76-78} and systemic sclerosis.\textsuperscript{79} Furthermore, ATG5 expression is elevated in both blood and brain-residing T-cells in multiple sclerosis patients and is associated with the relapsing-remitting disease phenotype.\textsuperscript{80} These \textit{ATG5} genetic variants are functionally linked to a differential ATG5 expression and exhibit gene-gene interactions with \textit{ATG7} and \textit{IRGM},\textsuperscript{81} thereby likely influencing the degree of activation of the autophagy process. Interestingly, ATG5 also plays an important role in clearing apoptotic cells,\textsuperscript{82} and a hallmark of SLE is the deficiency to clear apoptotic cells. Similar to CD, IRGM has also been implicated in multiple sclerosis based on the observation that IRGM expression is strongly induced in affected lesions of multiple sclerosis patients. Consistently, IRGM1-deficient mice are resistant to the experimental model of multiple sclerosis, antigen-induced experimental encephalomyelitis (EAE), by promoting blood-brain barrier integrity and preventing T cell infiltration into the central nervous system.\textsuperscript{83,84}

SLE is characterized by deregulation of autoantibody-producing B cells, infiltration of target organs by inflammatory T cells and aberrant immune cell activation. The latter is caused by abnormal activation of myeloid cells triggered by the presence of immune complexes composed of self-DNA from apoptotic cells and antibodies generated by autoreactive B cells.\textsuperscript{85,86}

While T cells are considered as a major cell type driving initiation and progression of SLE,\textsuperscript{87,88} innate immune cells are also implicated in the disease process. In this respect, inappropriate handling of apoptotic bodies by phagocytes leads to accumulation of autoantigens that could promote loss of tolerance, predisposing the organism to autoimmune responses.\textsuperscript{89,90} Autophagy is likely involved in these processes, since it influences T cell development and activation, but also because it executes clearance of apoptotic cells and contributes to the elimination of their immunogenic potential.\textsuperscript{91}

In rheumatoid arthritis (RA), a chronic inflammatory disorder affecting the joints, autophagy has a critical role in TNF-induced joint destruction (in murine experimental arthritis); TNF activates autophagy by induction of BECN1 and ATG7 and the conversion from MAP1LC3B-I to MAP1LC3B-II in osteoclasts, providing a mechanism for TNF-associated synovial inflammation and bone resorption.\textsuperscript{92} These findings suggest that TNF promotes autophagy-dependent osteoclast differentiation and survival, which is confirmed in human synovial fibroblasts.\textsuperscript{93-95}

### The role of autophagy in infectious diseases

In the fight against pathogenic microorganisms, autophagy (this form of autophagy is called xenophagy) contributes to both innate immune defense and to development of adaptive immune memory, and excellent recent reviews have described these mechanisms in great detail.\textsuperscript{86,97} The role of autophagy in infectious diseases is apparent at the level of microbial handling by the innate immune system, as well as antigen processing and presentation of a wide variety of microorganisms ranging from viruses, to bacteria, fungi, and protozoa.
Within the context of innate host defense, autophagy provides the machinery for intracellular killing of microbes by means of phagophore engulfment and lysosomal fusion. Proper designation of microorganisms for autophagy processing is facilitated by protein adaptors such as SQSTM1/p62, NBR1 and CALCOCO2, that are activated downstream of microbial recognition by pattern-recognition receptors (TLR, NLR, RLR), providing anchors for phagophore assembly around the selected cargo. Several intracellular signaling pathways have been described to induce autophagy by PRRs. Activation of a TLR4-TICAM1 pathway has been reported to induce autophagy by Gram-negative bacteria such as Pseudomonas aeruginosa, and cleavage of TICAM1 by CASP1 inhibits autophagy.100 In addition, another important factor for TLR-induced autophagy is activation of the IRF8 transcription factor, which in turn activates genes involved in autophagosome formation.101 Induction of autophagy by NLR receptors is induced by the interaction with the peptidoglycans that activate a RIPK2/RIP2 (receptor-interacting serine-threonine kinase 2)-dependent signaling pathway. Furthermore, a very important process during the induction of autophagy is represented by the interaction with molecular sensors of metabolites. In this respect, during antimycobacterial responses induction of autophagy necessitates activation of AMPK that induces PPARGC1A (peroxisome proliferator-activated receptor gamma, coactivator 1 α), leading to activation of oxidative phosphorylation, inhibition of MTOR, and induction of autophagy.104 A similar dependency on MTOR inhibition and induction of ROS is required for induction of autophagy by S. pneumonia.105

Autophagy is also important for the induction of T cell responses, and recent studies have underlined its crucial role for lymphocyte survival and memory. During infection with lymphocytic choriomeningitis virus autophagy is not required for proliferation and CD8+ T-effector function, but is crucial for long-term cell survival and memory.106 A similar role of autophagy for CD8+ memory was reported during influenza and MCMV infections.107 During influenza infection, Atg5 knockout mice display a defective lymphocyte survival and proliferation.108 Interestingly, chaperone-mediated autophagy regulates T cell responses through targeted degradation of negative regulators of T cell activation.109

At the level of autophagy-inflammation interaction, host defense mechanisms are directly influenced by the modulation of proinflammatory cytokines, as described above in detail. However, the host defense against various classes of microorganisms is not influenced to the same extent. One of the most important infections for which autophagy makes a major impact is tuberculosis. Several studies have demonstrated the crucial role of autophagy for elimination of mycobacteria. M. tuberculosis induces ubiquitin-mediated targeting in macrophages, resulting in delivery of the pathogen to autolysosomes. This response requires the autophagy receptors SQSTM1, CALCOCO2 and the DNA-responsive kinase TBK1 (TANK-binding kinase 1), while inhibition of MTOR through AMPK activation is a necessary change in metabolic status of the cell activating autophagy.104 In addition, antimycobacterial peptides are produced in a SQSTM1-dependent manner.111,112

Autophagy is also important in host defense against other intracellular pathogens such as Toxoplasma gondii,113,114 Salmonella spp,115,116 and Listeria monocytogenes.117 The role of autophagy for host defense against viruses strongly depends on the type of infection, and involves several mechanisms, especially those involved in autophagosome generation and maturation (as detailed in ref. 96), rather than inflammation. Autophagy is important for removal of herpes simplex virus-118 and Rift valley virus,119 and restricts HIV infection by degrading the HIV1 transactivator Tat in CD4+ lymphocytes.120 In addition, autophagy not only contributes to the elimination of the virus, but also controls IL1B induction and aberrant induction of IL17-dependent lung pathology in respiratory syncytial virus infection.121 Autophagy also proved important for the host defense against the fungal pathogen Cryptococcus neoformans, through mechanisms involving the nonlytic exocytosis of the fungus, but also interfering with production of the inflammatory mediators IL6 and CXCL10/IP-10 (chemokine [C-X-C motif] ligand 10).122 In contrast, no effect of autophagy for host defense against Candida albicans has been demonstrated.123,124 Despite the demonstration of CLEC7A/dectin-1-dependent accumulation of MAP1LC3B to phagosomes that increases in vitro killing of the fungus.125

Notably, pathogens have also evolved strategies to evade the immune response by taking advantage of the autophagy machinery. For instance, M. tuberculosis latently infects human immune cells by concealed residence in the autophagosome and by preventing lysosomal fusion. In addition, active mycobacterial infection counteracts autophagy through the induction of MIR30A that inhibits BECN1. Salmonella in turn attempts to inhibit autophagy and increase its survival by activating PTK2/focal adhesion kinase and MTOR. Furthermore, Listeria monocytogenes and Shigella, as well as viral pathogens such as HIV, have evolved different strategies to evade the autophagy machinery by inhibition of autophagosome formation or by modulation of positive (IFNA and IFNB-IL6 signaling) and negative upstream regulators (MTOR kinase signaling pathway) of autophagy.128-130

Genetic variants of autophagy genes have been investigated for their effects on antimicrobial immune responses, which revealed that the CD-associated ATG16L1 polymorphism impairs defense mechanisms against Salmonella typhimurium and increases susceptibility toward Helicobacter pylori infection.53,131 In addition, genetic variants of both ATG16L1 and IRGM are associated with sepsis, potentially through modulation of immunoparalysis.132,133 However, in a large cohort no significant predisposition was observed for polymorphisms in autophagy genes to develop M. tuberculosis infections, although autophagy profoundly influences the host immune response against this pathogen.134,135 Similar findings have been reported for mucosal and systemic infections caused by the fungus Candida spp, indicating the redundant role of autophagy in antifungal host defense.136,137

The impact of autophagy-inflammation interplay on carcinogenesis

Both autophagy and inflammation are involved in several steps of carcinogenesis and cancer progression. Autophagy has been
reported to have both antitumoral effects and tumor-promoting effects in cancer. The generally accepted explanation for this apparent ambiguous role of autophagy in cancer is that its role might differ in the different stages of carcinogenesis and in different tumor types and is related to changes in the tumor microenvironment and treatment. In addition, the dual role of autophagy in cancer might reflect the interplay between autophagy and other fundamental biological processes such as apoptosis, senescence, cell metabolism, and the immune system.\textsuperscript{138,139}

In the early stages of cancer development, defects in autophagy machinery or inhibition of autophagy in premalignant cells might result in impaired degradation and removal of damaged organelles, unfolded proteins and ROS. These cytosolic components, which might accumulate in the cells, produced as a result of activation of oncogenic pathways result in DNA damage and maintain the carcinogenic phenotype.\textsuperscript{140,141} In mice, monoallelic deletion of haplo-insufficient \textit{Becn1}, results in autophagy deficiency, leads to spontaneous development of malignant tumors, and stimulates development of hepatitis-B-induced premalignant liver lesions.\textsuperscript{142} Other studies indicate that \textit{Becn1} represents an important tumor suppressor and an increased \textit{Becn1} expression is associated with a favorable prognosis in several cancers.\textsuperscript{143-146} Moreover somatic mutations in \textit{ATG} genes have been described in different malignant tumors.\textsuperscript{147,148} In addition, somatic mutations and/or genetic amplifications in \textit{AKT1} and class I phosphoinositide 3-kinase (PI3K) and somatic or germ-line mutations leading to inactivation of the tumor suppressor gene \textit{PTEN} are often found in malignant tumors.\textsuperscript{149-153} As a result, signaling molecules upstream of \textit{MTOR} such as \textit{AKT1} and class I PI3K are activated and exert inhibitory effects on autophagy in malignant transformed cells. AKT1 can inhibit autophagy either through activation of \textit{MTOR} or through \textit{MTOR}-independent mechanisms such as \textit{Becn1} phosphorylation and formation of an autophagy-inhibitory \textit{Becn1}-YWHA/14–3–3-VIM/vimentin intermediate filament complex.\textsuperscript{154} The class III phosphatidylinositol 3-kinase (PtdIns3K) is an intracellular lipid kinase that has crucial functions in autophagosome formation, vesicular trafficking and endocytosis.\textsuperscript{155} In addition these lipid kinases represent key signaling molecules that play important roles in carcinogenesis. Three classes of phosphoinositide and phosphatidylinositol 3-kinases have been described according to their structure and substrate specificity. Of these, the functions of class I and of class III enzymes are best understood. Class III PtdIns3K phosphorylates phosphatidylinositol to form phosphatidylinositol-3-phosphate. The catalytic subunit of class III PtdIns3K, PIK3C3/Vps34, binds to other regulatory proteins, including ATG14, and contributes to the induction of autophagosome formation. In cancer, however, class I PI3Ks are often activated and therefore their role has been better explored as potential targets for therapy in malignant processes. In contrast to class III PtdIns3K, class I PI3K is activated downstream of receptor tyrosine kinases and G-protein coupled receptors and upon activation phosphorylates phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-trisphosphate. Through this, PI3K activates AKT and MTOR, which in turn promotes cell survival and proliferation and suppresses autophagy.\textsuperscript{156-158} Altogether, these studies suggest that autophagy genes can act as tumor suppressor genes in several tumors, and suppressed or defective autophagy may play an important role in tumor initiation.

Conversely, in the more advanced stages of tumor development and progression, once the carcinogenic phenotype has been established, the cancer cells rely on autophagy to support the requirements for energy and provide substrates necessary for proliferation. This is especially important for surviving in an unfavorable microenvironment characterized by severe hypoxia and nutrient-deficient conditions. Therefore activation of autophagy in this context could be regarded as a survival factor, promoting cell proliferation and tumor progression. This is particularly relevant in the context of therapeutic response to cytotoxic agents and ionizing radiation. The strong induction of autophagy observed as a result of treatment with ionizing radiation or chemotherapy may contribute to cell survival and the acquired resistance to therapy in many cancer cells including breast cancer, pancreatic cancer, and malignant glioma.\textsuperscript{159-162} For this reason, inhibition of autophagy with chloroquine or hydroxychloroquine in combination with radiotherapy or chemotherapy has been investigated as a strategy to prevent therapy resistance and sensitize tumors to therapy.\textsuperscript{163-167} However, in the context of excessive activation autophagy may lead to cell death in cells lacking apoptotic machinery, in which the programmed cell death takes place preferentially through autophagic cell death.\textsuperscript{168-172} Several mechanisms have been postulated to explain these apparently conflicting roles of autophagy in tumorigenesis. These include involvement of autophagy in cell death and cell survival through an intricate interplay with apoptosis and necrosis by shaping the metabolic and oxidative stress environment of the cell, its role in quality control for the homeostasis of proteins and organelles, and its function in the modulation of tumor-targeted immune responses.\textsuperscript{138,173} However the exact regulatory mechanisms of this dynamic process are not completely understood and due to the length and the focus of this review this will not be further discussed here. We will focus instead on the role and the consequences of the interplay between autophagy and inflammation in cancer pathogenesis and treatment.

The relationship between inflammation and cancer has long been recognized. Many chronic inflammatory conditions, such as inflammatory bowel disease, chronic hepatitis, or pancreatitis are clearly recognized as precursors of malignancies in the respective organs.\textsuperscript{174-177} Moreover, the immune system is the most important defense mechanism that identifies and eliminates malignant transformed cells and prevents tumor progression and metastasis. Autophagy has a modulatory role that shapes the interface between cancer and immune response, including effects on both tumor cells and immune cells, which subsequently influence the survival and function of, and interplay between, these cells and ultimately results in either tumor-promoting or tumor-suppressing effects (Fig. 4).

It is well known that tumor cells rely on aerobic glycolysis to support their energy requirements and to enable increased protein production (historically known as the Warburg effect).\textsuperscript{178,179} This mode of growth, however, requires an increased influx of glucose, which is often not available in parts
of the tumor that have no or only limited access to (neo)vascularization. As described above, in conditions of glucose or amino acid deprivation and hypoxia autophagy is activated as an important survival mechanism. However, oncogenic events, such as mutations in the PI3K-AKT-MTOR signaling pathway, have anti-apoptotic effects and inhibit autophagy simultaneously. This impairs the activation of autophagy as a compensatory survival mechanism and renders the tumor cells prone to necrosis.\(^{180}\) In cancer, necrosis is seen as an unfavorable event because it results in release of highly inflammatory molecules, such as uric acid, ATP/UTP, HMGB1 (high mobility group box 1), and other damage-associated molecular patterns (DAMPs).\(^{181-183}\) All together, these inflammatory mediators and DAMPs promote and maintain malignant features such as cell survival and proliferation and contribute to recruitment of macrophages and other specialized antigen-presenting cells such as DCs.\(^{184}\) These cells in turn stimulate inflammation in the peritumoral stroma and induce a pro-tumorigenic environment that promotes angiogenesis, tumor progression, and metastasis.\(^{180}\)

Although not an inflammatory mechanism itself, it is also important to underline that antigen recognition and presentation is the cornerstone of the specific immune responses against malignant cells. Hence, proper functioning of these processes heavily depends on the integrity of the autophagy machinery. It has for instance been shown that autophagy facilitates antigen presentation by tumor cells, such as human embryonic kidney cells (HEK293T) and melanoma cells, thereby facilitating the recognition of these cells by immune cells and their subsequent removal.\(^{185}\)

In addition, autophagy induces cellular senescence, a physiological state of sustained cell cycle arrest characterized by a senescence-associated secretory phenotype. This consists of increased expression and secretion of several cytokines, chemokines, growth factors, and proteases in the senescent cells,\(^{186}\) which stimulate on the one hand the recruitment and activation of phagocytes responsible for the removal of these cells, and on the other hand contribute to maintenance of the senescent phenotype. Subsequently, failure to induce autophagic flux and immune-mediated senescence increases the susceptibility to hepatocellular carcinoma in a mouse model.\(^{187}\)

The interplay between autophagy and inflammation is particularly interesting in the context of therapeutic implications, and the concerted targeting of these 2 processes can be explored for novel strategies. TNFSF10/TRAIL (tumor necrosis factor [ligand] superfamily, member 10) induces cell death in different cancer cells and therefore contributes to immune cell-mediated cytotoxicity.\(^{188-190}\) However, pharmacological treatment with recombinant ligands has been hampered by the occurrence of therapy resistance.\(^{191}\) Nevertheless, blocking autophagy in the FRO anaplastic thyroid cancer cell line with ATG7 siRNA sensitizes the cells to TNFSF10-induced apoptosis, indicating that modulation of autophagy holds important therapeutic potential for anticancer treatment.\(^{192}\)

Moreover, autophagy plays an important role in the response to chemotherapy of some tumors, in particular through influencing the immune response in the tumor microenvironment. Treatment with chemotherapy can induce immunogenic cell death.\(^{193}\) In this process, macrophages and

---

**Figure 4.** The role of crosstalk between autophagy and inflammation in cancer. Induction of autophagy is a double-edged sword with both protumorigenic and antitumorigenic effects. Processes downstream of autophagy that influence tumor progression and treatment resistance are comprised of cell survival pathways and recruitment of innate immune cells following release of DAMPs by necrotic tumor cells. Conversely, antitumorigenic signaling is evoked by autophagy-mediated immunogenic cell death and inhibition of tumor-associated inflammation. An outstanding example of the diverse and apparently opposite effects of autophagy on cancer initiation and progression is the induction of cellular senescence and subsequent removal of senescent cells; depending on the cellular context this is either pro- or anti-tumorigenic. APC, antigen-presenting cell.
DCs are attracted and recruited in the peritumoral stroma by molecules exposed at the cell surface or released in the tumor microenvironment as a result of apoptosis and necrosis following treatment with chemotherapeutic agents. DCs engulf the damaged tumor cells (remnants) and activate T-cells through antigen-presentation. These cells exert an antitumoral effect on the remaining unaffected cancer cells, thus enhancing the antitumoral effect of the chemotherapeutic agent. Michaud et al. have shown in cell lines and mouse models that autophagy is crucial for ATP release by the chemotherapy-induced dying tumor cells and for the induction of the antitumoral immunogenic response. It has even been suggested that autophagy in modulation of inflammation is only in its beginning in the setting of understanding the pathophysiology of different types of cancer, and remains nearly untouched in autoimmune and autoinflammatory diseases. Understanding its role in tissue repair and remodeling is also an important challenge for the future.

Finally and most importantly, modulation of autophagy activity may represent a promising therapeutic approach for a wide range of inflammatory conditions. In this respect, a recent study reported the development of an autophagy-inducing peptide, Tat-BECN1, which decreased the replication of several human pathogens in vitro, and reduced mortality in mice infected with chikungunya or West Nile virus. However, at the same time, autophagy is a fundamental evolutionarily conserved process, and detailed knowledge about autophagy is necessary regarding its role in different diseases, cell types, and timelines, in order to avoid improper (or even dangerous) manipulation of a process fundamental for cell integrity. Nevertheless, future investigations are warranted in order to pursue novel autophagy-directed therapeutic approaches to effectively treat the ever-growing number of patients suffering from immune-mediated disorders.

**Abbreviations**

- AMP: adenosine monophosphate
- AMPK: 5′ AMP-activated protein kinase
- ATG: autophagy related
- ATP: adenosine triphosphate
- BCG: Bacillus Calmette-Guérin
- BECN1: Beclin 1, autophagy related
- CD: Crohn disease
- CGD: chronic granulomatous disease
- CXCL10/IP-10: chemokine (C-X-C motif) ligand 10
- DAMP: danger-associated molecular pattern
- DC: dendritic cell
- EAE: experimental autoimmune encephalo-myelitis
- ENTPD1: guanosine 5′-triphosphate
- IFN: interferon
- IKBKB/IκBα: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
- IL: interleukin
- IL1RN/ILR1A: interleukin 1 receptor antagonist
- IRGM: immunity-related GTPase family, M
- LAP: lipopolysaccharide
- LAP: lipopolysaccharide
- MAP1LC3B: microtubule-associated protein 1 light chain 3 beta
- MAPK: mitogen-activated protein kinase
- mDNA: mitochondrial DNA
- MAPK: mitogen-activated protein kinase
- MCH: mechanism of target of rapamycin (serine/threonine kinase)
- NADPH: nicotinamide adenine dinucleotide hydrogen phosphate
- NLR: NOD-like receptor
- NLRP3: NLR family, pyrin domain containing 3
- NLRP3: NLR family, pyrin domain containing 3
- NFKB: nuclear factor of kappa light polypeptide gene enhancer in B-cells, kinase beta
- NLRP3: NLR family, pyrin domain containing 3
- PKC: protein kinase C
- PPI: peptidylprolyl isomerase
- RIGM: receptor-interacting protein 1
- SLC35A2: solute carrier family 35, member 2
- SQSTM1: sequestosome 1
- TLR: toll-like receptor
- TAT: transactivator of transcription
- TNF: tumor necrosis factor
- TRIF: TIR-domain containing adaptors inducing interferon-

**Conclusions and future perspectives**

Autophagy influences several key components of the immune response, and thus plays a critical role in regulating inflammatory responses. It has even been suggested that autophagy evolved as a primordial host defense mechanism of eukaryotes. As evolution progressed, autophagy has intimately integrated with the other components of host defense, including the inflammatory reaction.

Despite the increasing knowledge about the role of autophagy in modulation of inflammation, this field is still only in its beginnings. Little is known about the involvement of the autophagy-related SQSTM1-like receptors for the modulation of inflammation, although some initial data have suggested important effects. The pathophysiological relevance of autophagy-inflammation interplay has not been studied yet in the context of colonization of mucosal membranes, and detection of tissue invasion. The influence of autophagy for directing polarization of adaptive immune responses (e.g., Th1 vs. Th2 vs. Th17) also warrants additional study in the coming years. In addition, the study of the balance between induction of autophagy and inhibition of inflammation is only in its beginning in the setting of understanding the pathophysiology of different types of cancer, and remains nearly untouched in autoimmune and autoinflammatory diseases. Understanding its role in tissue repair and remodeling is also an important challenge for the future.
Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

MGN was supported by a Vici grant of the Netherlands Organization for Scientific Research and by an ERC Consolidator Grant (#310372). TSP was supported by a Veni grant of the Netherlands Organization for Scientific Research and by the Alpe d’Huües fund of the Dutch Cancer Society (KUN2014–6728). FV was supported by a Veni grant of the Netherlands Organization for Scientific Research.

References

1. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol 2010; 12:814-22; PMID:20811353; http://dx.doi.org/10.1038/ncc0910-814

2. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev Immunol 2012; 30:611-46; PMID:22449030; http://dx.doi.org/10.1146/annurev-immunol-020711-074948

3. Deretic V, Saitoh T, Akira S. Autophagy in infection, in immune system. Annu Rev Immunol 2012; 30:611-46; PMID:22449030; http://dx.doi.org/10.1038/nm.2069

4. Heath RJ, Xavier RJ. Autophagy, immunity and human disease. Curr Opin Gastroenterol 2009; 25:512-20; PMID:19826372; http://dx.doi.org/10.1097/MOG.0b013e32833104f1

5. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 2011; 27:107-32; PMID:21801009; http://dx.doi.org/10.1146/annurev-cellbio-092910-154005

6. Virgin HW, Levine B. Autophagy genes in immunity. Nat Immunol 2009; 10:461-70; PMID:19381141; http://dx.doi.org/10.1038/nmi.1726

7. Henaut J, Martinez J, Riggs JM, Tian J, Mehta P, Clarke L, Sasai M, Latz E, Brinkmann MM, Iwaski A, et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 2012; 37:986-97; PMID:23219390; http://dx.doi.org/10.1016/j.immuni.2012.09.014

8. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Münz C. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005; 307:593-6; PMID:15591165; http://dx.doi.org/10.1126/science.1104904

9. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature 2008; 455:396-400; PMID:18701890; http://dx.doi.org/10.1038/nature07208

10. Buffen K, Oosting M, Quintin J, Ng A, Kleinijnenhuis J, Kumar V, van de Vosse E, Wijmenga C, van Crevel R, Oosterwijk E, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS pathogens 2014; 10:e1004485; PMID:25356988; http://dx.doi.org/10.1371/journal.ppat.1004485

11. Dijk CS, Kehel JH, TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal 2010; 3a42; PMID:20501938

12. Nazio F, Strappaflon F, Antonioli M, Bielli P, Cianflanelli V, Bordi M, Gremetzki C, Dengel J, Piacentini M, Finnia GM, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol 2013; 15:406-16; PMID:23524951; http://dx.doi.org/10.1038/ncllb2708

13. Xu Y, Liu XD, Gong X, Eissa NT. Signaling pathway of autophagy associated with innate immunity. Autophagy 2008; 4:110-2; PMID:18059159; http://dx.doi.org/10.4161/auto.4.4.9252

14. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J 2008; 27:1110-21; PMID:18337753; http://dx.doi.org/10.1038/embj.2008.31

15. Cooney R, Baker J, Brain O, Das B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nature 2010; 16:90-7; PMID:19966812; http://dx.doi.org/10.1038/nm.2069

16. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, Yuan L, Soares F, Chea E, Le Bourhis L, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55-62; PMID:19898471; http://dx.doi.org/10.1038/ni.1823

17. Mostowy S, Sancho-Shimizu V, Hamon MA, Simeone R, Brosch R, Johansen T, Cossart P, Pelle and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. J Biol Chem 2011; 286:26987-95; PMID:21646350; http://dx.doi.org/10.1074/jbc.M111.223610

18. Hartman ML, Kornfeld H. Interactions between naive and infected macrophages reduce Mycobacterium tuberculosis viability. PloS One 2011; 6:e27972; PMID:22125644; http://dx.doi.org/10.1371/journal.pone.0027972

19. Singh SB, Ornatowski W, Vergne I, Naylor J, Delgado M, Roberts E, Ponpuak M, Master S, Pelle and ND52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. J Biol Chem 2011; 286:26987-95; PMID:21646350; http://dx.doi.org/10.1074/jbc.M111.223610

20. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119:753-66; PMID:15607973; http://dx.doi.org/10.1016/j.cell.2004.11.038

21. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006; 313:1438-41; PMID:16688103; http://dx.doi.org/10.1126/science.1129577

22. Tallocco Z, Jiang W, Virgin HWt, Leib DA, Scheuner D, Kaufman RJ, Reskelien EL, Levine B. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc Natl Acad Sci U S A 2002; 99:190-5; PMID:11756670; http://dx.doi.org/10.1073/pnas.012485299

23. Feng CG, Zheng L, Jankovic D, Bünz D, Böttcher A, Cannons JL, Watford WT, Chauzabal D, Hieny S, Caspar P, Schwartzberg PL, et al. The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. Nat Immunol 2008; 9:1279-87; PMID:18806793; http://dx.doi.org/10.1038/ni.1653

24. Internemann CD, Thye T, Niemann S, Browne EN, Amanu Chinbuah M, Ennial M, Gyapong J, Osiri I, Owusu-Dabo E, Halm S, et al. Autophagy gene variant IRGM-261T contributes to protection from...
tuberculosis caused by Mycobacterium tuberculosis but not by M. africanaum strains. PLoS Pathogens 2009; 5:e1000577; PMID:19730224; http://dx.doi.org/10.1371/journal.ppat.1000577

25. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med 2009; 15:267-76; PMID:19252503; http://dx.doi.org/10.1038/nm.1928

26. Harris J, De Haro SA, Master SS, Keane J, Roberts EA, Delgado M, Deretic V. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007; 27(3):505-17; PMID:17892853; http://dx.doi.org/10.1016/j.immuni.2007.07.022

27. Zhou D, Spector SA. Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS 2008; 22:695-9; PMID:18356598; http://dx.doi.org/10.1097/QAD.0b013e3282a4836

28. Deretic V, Singh S, Master S, Harris J, Kyei G, Davis A, de Vrind RC, Kullberg BJ, van der Meer JW, Joosten LA, Netea MG. Inhibition of mitochondrial DNA mediated by the NALP3 in inflammasome activation. Nature 2011; 469:221-5; PMID:21124315; http://dx.doi.org/10.1038/nature09663

29. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 476:264-8; PMID:21884965; http://dx.doi.org/10.1038/nature10738

30. Nakamura K, Kuhl L, Li Y, Yang F, Aiello A, Kenna M, Scholze B, Nagy L, Welsh M, Pfeffer K, et al. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 2011; 286:9587-97; PMID:21228274; http://dx.doi.org/10.1074/jbc.M110.202911

41. Giegerich AK, Kuchler L, Sha IK, Knape T, Heide H, Wittig I, Behrends C, Brüne B, von Knethen A. Autophagy-dependent PELI3 degradation inhibits proinflammatory IL-1B expression. Autophagy 2014; 10:1937-52; PMID:25483963; http://dx.doi.org/10.4161/auto.32178

55. Wildenberg ME, Vos ACW, Wolkamp SC, Duijvestein M, Verhaar AP, Te Velde AA, van den Brink GR, Hommes DW. Autophagy attenuates the adaptive immune response by destabilizing the
immunologic synapse. Gastroenterology 2012; 142:1493-503.e6; PMID:22370477; http://dx.doi.org/10.1053/j.gastro.2012.02.034

56. Striscigliucio C, Miele E, Wildenberg ME, Giugliano FP, Andreozzi M, Vitale A, Capasso F, Camarca A, Barone MV, Staiano A, et al. T300A variant of autophagy ATG16L1 gene is associated with decreased antigen sampling and processing by dendritic cells in pediatric chronic granulomatous disease. Inflamm Bowel Dis 2013; 19:2339-48; PMID:24022642; http://dx.doi.org/10.1097/MIB.0b013e3182e6a11c

57. Plantinga TS, Crisam TO, Oosting M, van de Veerdonk FL, de Jong DJ, Philpott DJ, van der Meer JW, Girardin SE, Joosten LA, Netea MG. Crohn’s disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 2011; 60:1229-35; PMID:21406388; http://dx.doi.org/10.1136/gut.2010.228908

58. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Sato T, Omori H, Noda T, Yamaamoto N, Komatsu M, et al. Loss of the autophagy protein Atg16l1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456:264-8; PMID:18849965

59. Crisan TO, Plantinga TS, van de Veerdonk FL, Farcaş MF, Stoffels M, Kullberg BJ, van der Meer JW, Joosten LA, Netea MG. Inflammation-independent modulation of cytokine response by autophagy in human cells. PLoS One 2011; 6:e18666; PMID:21278745; http://dx.doi.org/10.1371/journal.pone.0018666

60. Brest P, Lapauquette S, Pousidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barby P, Mosnier JF, Hébuterne X, et al. A synonymous variant in IRGM alters a binding site for mir-196 and causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat Genet 2011; 43:242-5; PMID:21278745; http://dx.doi.org/10.1038/ng.762

61. McCarroll SA, Huet D, Kupalla P, Chlewski SD, Landry A, Goyette MF, Stoffels MF, Stoffels,§ H, Noda T, Yamamoto N, Komatsu M, et al. Association between variants of PRDM1 and NDP52 and Crohn disease. Nat Genet 2008; 40:1107-12; PMID:19165925; http://dx.doi.org/10.1038/ng.2151

62. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cérard JP, Belaiche J, Almer S, Tysk C, Ofer G, Mosner JF, Houben M, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn disease. Nature 2001; 411:603-6; PMID:11385577; http://dx.doi.org/10.1038/35079107

63. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411:603-6; PMID:11385577; http://dx.doi.org/10.1038/35079114

64. Travassos LH, Carneiro LAM, Ramjeet M, Travassos LH, Jones NL, Girardin SE, Philpott DJ. The protein ATG16L1 suppresses inflammatory cytokines induced by the intracellular sensors Nod1 and Nod2 in an autophagy-independent manner. Immunity 2013; 39:858-73; PMID:24238340; http://dx.doi.org/10.1016/j.immuni.2013.10.013

65. Ellinghaus D, Zhang H, Zeissig S, Lipski S, Tll A, Jiang T, Stade B, Bromberg Y, Ellinghaus E, Keller A, et al. Association between variants of PRDM1 and NDP52 and Crohn’s disease, based on exome sequencing and functional studies. Gastroenterology 2013; 145:339-50; PMID:23621408; http://dx.doi.org/10.1053/j.gastro.2013.04.040

66. Thurston TLM, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat Immunol 2009; 10:1135-41; PMID:19688471; http://dx.doi.org/10.1038/nl.1823

67. Zoccai GG, Houser JE, Qureshi IZ, Obery ED, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117:2670-83; PMID:18474815; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.740233

68. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, Ortmann W, Kosoy R, Ferreira RC, Nordmark G, et al. A large-scale replication study identifies TNIP1, PRD1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41:1228-33; PMID:19683195; http://dx.doi.org/10.1038/ng.468

69. International Consortium for Systemic Lupus Erythematosus G, Harley JB, Alarcon-Riquelme ME, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40:204-10; PMID:18204446; http://dx.doi.org/10.1038/ng.81

70. Zhou X-J, Lu X-L, Lv J-C, Yang HZ, Qin LX, Zhao MH, Su Y, Li ZG, Zhang H. Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis 2011; 70:1330-7; PMID:21622776; http://dx.doi.org/10.1136/ard.2010.140111

71. Mayes MD, Bossini-Castillo L, Gorlова O, Martin JE, Zhou X, Chen WV, Assassi S, Ying T, Fan K, Arnett FC, et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Ann Rheum Dis 2014; 73:47-53; PMID:24387989; http://dx.doi.org/10.1136/ard.2013.183122

72. Alirezaei M, Fox HS, Flynn CT, Moore CS, Hebb AL, Frausto RF, Zoccai GG, Houser JE, Qureshi IZ, Obery ED, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117:2670-83; PMID:18474815; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.740233

73. de Luca A, Salloum FN, Veele C, Das A, Hoke NK, Straino S, Biond-Zoccai GG, Houser JE, Qureshi IZ, Obery ED, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117:2670-83; PMID:18474815; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.740233
110. Reed M, Morris SH, Owczarczyk AB, Lukacs NW. De Sagnier S, Daussy CF, Borel S, Robert-Hebmann V, Faure M, Blan... 2015; 89:615-25; PMID:25339774; http://dx.doi.org/10.1128/JVI.02174-14

111. Zhao Z, Fux B, Goodnow CC, Dunay IR, Strong D, Miller BC, Cadwell K, Delgado MA, Ponpuak M, Green KG, et al. Autophagosome-independent essential function for the autophagy protein ATg5 in cellular immunity to intracellular pathogens. Cell Host Microbe 2008; 4:458-69; PMID:18996346; http://dx.doi.org/10.1016/j.chom.2008.10.003

112. Liesenfeld O, Parvanova I, Zerrahn J, Han SJ, Heinrich F, Muñoz K, Kaiser F, Aebischer T, Buch T, Waismann A, et al. The IFN-gamma-inducible GTPase, Irga6, protects mice against Toxoplasma gondii but not against Plasmodium berghei and some other intracellular pathogens. PloS One 2011; 6:e20568; PMID:21698150; http://dx.doi.org/10.1371/journal.pone.0020568

113. Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, Brady NR, Richter B, Korac J, Waidmann O, Choudhary C, et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011; 332:228-33; PMID:21617041; http://dx.doi.org/10.1126/science.1205405

114. Pankiv S, Clausen TH, Lamark T, Breh A, Bruun JA, Outzen H, Øvrebøt A, Bjerkøy G, Johansen T, p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc.M702824200

115. Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, Kim M, Mimuro H, Nakagawa I, Yanagawa T, Ishii T, et al. Listeria monocytophages by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc.M702824200

116. Raju D, Hussey S, Jones NL. Crohn disease ATG16L1 polymorphism increases susceptibility to infection with Helicobacter pylori in humans. Autophagy 2012; 8:1387-8; PMID:22885761; http://dx.doi.org/10.104161/auto.21007

117. Smeekens SP, Malireddi RK, Plantinga TS, Farcas M, Baziaka F, Rafiogianis M, Orfanos SE, Dimopoulos G, Netea MG, Gianniello-Bourboulis EJ. Association of autophagy-related 16-like 1 (ATG16L1) gene polymorphism with sepsis severity in patients with sepsis and ventilator-associated pneumonia. Eur J Clin Microbiol Infect Dis 2011; 30:1609-14; PMID:21479195; http://dx.doi.org/10.1007/s10096-011-1418-7

118. Kleinnijenhuis J, Oosting M, Plantinga TS, van der Meer JW, Joosten LA, Crevel RV, Netea MG. Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. Immunology 2011; 134:341-8; PMID:21978003; http://dx.doi.org/10.1111/j.1365-2567.2011.03494.x

119. Songane M, Kleinnijenhuis J, Alipparda B, Sahiramadja E, Parwati I, Oosting M, Plantinga TS, Joosten LA, Netea MG, Ottenhoff TH, et al. Polymorphisms in autophagy genes and susceptibility to tuberculosis. PLoS One 2012; 7:e41618; PMID:22879892; http://dx.doi.org/10.1371/journal.pone.0041618

120. Rosentul DC, Plantinga TS, Farcas M, Oosting M, Hamza OJ, Scott WK, Alexander BD, Yang JC, Laird GM, Joosten LA, et al. Role of autophagy genetic variants for the risk of Candida albicans infections. Med Mycol 2014; 52:333-41; PMID:24713404; http://dx.doi.org/10.1093/mycopathology/myt035

121. Smeekens SP, Malireddi RK, Plantinga TS, Buffen K, Oosting M, Joosten LA, Pullberg BJ, Perfect JR, Scott WK, van de Veerden FL, et al. Autophagy is redundant for the host defense against systemic candidal infections. Eur J Clin Microbiol Infect Dis 2014; 33:711-22; PMID:24202731; http://dx.doi.org/10.1007/s10096-013-2002-x

122. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011; 32:955-63; PMID:21317301; http://dx.doi.org/10.1093/carcin/bgr031

123. Mah LY, Ryan KM. Autophagy and cancer. Cold Spring Harb Perspect Biol 2011; 3:1-24; PMID:21761315; http://dx.doi.org/10.1101/cshperspect.a008821

124. Dewaele M, Maes H, Agostinis P. ROS-mediated mechanisms of autophagy. Cell Host Microbe 2009; 11:1233-40; PMID:19749745; http://dx.doi.org/10.1016/j.chom.2008.10.003

125. Boumont I, Mansour MK, Khan NS, Seward M, Puranam S, Tanne A, Sokolovska A, Becker CE, Acharya M, Baird MA, et al. Dectin-1-dependent LC3 recruitment to phagosomes enhances fungicidal activity in macrophages. J Infect Dis 2014; 210:1844-54; PMID:24842831; http://dx.doi.org/10.1093/infdis/jiu290
tumorigenesis through elimination of p62. Cell 2009; 137:1062-75; PMID:19524509; http://dx.doi.org/10.1016/j.cell.2009.03.048

142. Qu X, Yu J, Bhagat G, Furuya N, Bihshooh H, Trexel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112:1809-20; PMID:14638851; http://dx.doi.org/10.1172/JCI20031151

143. Miracco C, Cevenini G, Franchi A,uzzi P, Cocci E, Mournouras V, Moncianti I, Mannucci S, Biagioli M, Toscano M, et al. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol 2010; 41:503-12; PMID:20004946

144. Cicchini M, Chakrabartii R, Kongara S, Price S, Nahar R, Lozy F, Zhong H, Vazquez A, Kang Y, Karantza V. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy 2014; 10:2036-52; PMID:25483966; http://dx.doi.org/10.4161/auto.34398

145. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999; 402:672-6; PMID:10064474; http://dx.doi.org/10.1038/365257a

146. Zhao Y, Chen S, Gou WF, Xiao LJ, Takano Y, Zheng HC. Aberrant Beclin 1 expression is closely linked to carcino genesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma. Tumour Biol 2014; 35:1955-64; PMID:24132590; http://dx.doi.org/10.1007/s13277-013-1261-6

147. Kang MR, Kim MS, Oh JE, Kim YR, Kim YJ, Ahn CH, Yoo NJ, Lee SH. Frameshift mutations of autophagy-related genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability. J Pathol 2009; 217:702-6; PMID:19197948; http://dx.doi.org/10.1002/path.2509

148. Kim MS, Jeong EG, Ahn CH, Kim SS, Lee SH, Yoo NJ. Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability. Hum Pathol 2008; 39:1059-63; PMID:18495205; http://dx.doi.org/10.1016/j.humpath.2007.11.013

149. Hou P, Liu D, Shan Y, Hu S, Sudeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase pathway in human cancer. Nat Rev Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839

150. Scott RC, Juhasz G, Neufeld TP. Direct induction of autophagy by Bcl-2 antiapoptotic proteins and brakes of autophagy. FEBS J 2013; 280:6322-37; PMID:24145178; http://dx.doi.org/10.1111/febs.12486

151. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology 2013; 145:1133-43e12; PMID:23916944; http://dx.doi.org/10.1053/j.gastro.2013.07.048

152. Wang P, Zhang L, Chen Z, Meng Z. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy 2013; 9:2171-2; PMID:24145177; http://dx.doi.org/10.4161/auto.26463

153. Lomonaco SL, Finissi S, Xiang C, Decarvalho A, Umansky F, Kalka SS, Muk kelsen SN, Mikkelson T, Brodie C. The induction of autophagy by Gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009; 125:17-22; PMID:19431142; http://dx.doi.org/10.1002/ijc.24402

154. Zanotto-Filho A, Braganhol E, Klafke K, Figueira F, Terra SR, Paludo FJ, Morrone M, Bristot IJ, Battistini AM, Forcellini CM, et al. Autophagy inhibition improves the efficacy of curcumin/temozolome combination therapy in glioblastomas. Cancer Lett 2015; 358:220-31; PMID:25542083; http://dx.doi.org/10.1016/j.canlet.2014.12.044.

155. Rosenberg MR, Ye X, Supko JG, Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10:1359-68; PMID:24991840; http://dx.doi.org/10.4161/auto.28994

156. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heijian DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1369-79; PMID:24991839; http://dx.doi.org/10.4161/auto.29118

157. Rangwala R, Chang YC, Hu J, Alagzy KM, Evans TL, Fecher LA, Schuchter LM, Torigan DA, Panosian J, Trexel AB, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10:1391-402; PMID:24991838; http://dx.doi.org/10.4161/auto.29119

158. Poklepovic A, Gewirtz DA. Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. Autophagy 2014; 10:1478-80; PMID:24991829; http://dx.doi.org/10.4161/auto.29428

159. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bel-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005; 122:927-39; PMID:16179260; http://dx.doi.org/10.1016/j.cell.2005.07.002

160. Scott RC, Juhasz G, Neufeld TP. Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death. Curr Biol 2007; 17:1-11; PMID:17208179; http://dx.doi.org/10.1016/j.cub.2006.10.053

161. Bursch W, Karwan A, Mayer M, Dornetshuber J, Fr et al. Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology 2008; 254:147-57; PMID:18694801; http://dx.doi.org/10.1016/j.tox.2008.07.048

162. Lomonaco SL, Galluzzi L, Kroemer G. Cell biology. Metabolic control of inflammation. Biochemical Society Trans 2012; 40:288-92; PMID:22921383; http://dx.doi.org/10.1042/bst0402882

163. Hawkins PT, Stephens LP. PI3K signalling in inflammation. Biochimica et Biophysica Acta 2015; 1851:882-97; PMID:25514767; http://dx.doi.org/10.1016/j.bbabio.2014.12.006
173. Marino G, Nisco-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 2014; 15:81-94; PMID:24401948; http://dx.doi.org/10.1038/nrm3735

174. Kuper H, Ye W, Broome U, Romelsjo A, Miceli RA, Ehrenfeld A, Adami HO, Trichopoulos D, Nyren O. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001; 34:714-8; PMID:1183467; http://dx.doi.org/10.1053/heap.2001.28233

175. Xing S, Li ZW, Tian YF, Zhang LM, Li MQ, Zhou P. Chronic hepatitis B virus infection increases the risk of pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int 2013; 12:575-83; PMID:24322741; http://dx.doi.org/10.1016/S1499-3872(13)60091-0

176. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andreason Sandberg A, Domellof L. Pancreatitis and the risk of pancreatic cancer. International pancreatitis study group. New Engl J Med 1993; 328:1433-7; PMID:8479461; http://dx.doi.org/10.1056/NEJM1993052032820.301

177. Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol 2014; 20:9872-81; PMID:25110418; http://dx.doi.org/10.3748/wjg.v20.i29.9872

178. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:21508972; http://dx.doi.org/10.1126/science.123.3191.309

179. Koppenol WH, Bounds PL, Dang CV. Otto Warburg: the release of damaged-associated molecular patterns and its physiological relevance. Immunity 2013; 38:209-23; PMID:23438821; http://dx.doi.org/10.1016/j.immuni.2013.02.003

180. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mulkerjee C, Shi Y, Gelin C, Fan Y, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorgenesis. Cancer Cell 2006; 10:51-64; PMID:16843265; http://dx.doi.org/10.1016/j.ccr.2006.06.001

181. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-5; PMID:12110890; http://dx.doi.org/10.1038/nature00858

182. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013; 38:209-23; PMID:23438821; http://dx.doi.org/10.1016/j.immuni.2013.02.003

183. Krysko O, Love Aaes T, Bachtet C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Cell Dis 2013; 4:e631; PMID:23681226; http://dx.doi.org/10.1038/cddis.2013.156

184. Hou W, Zhang Q, Yan Z, Chen R, Zeh lii HJ, Kang R, Lotze MT, Pancreatitis study group. New Engl J Med 1993; 328:1433-7; PMID:8479461; http://dx.doi.org/10.1038/heap.2001.28233

185. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008; 68:8889-95; PMID:18757401; http://dx.doi.org/10.1158/0008-5472.CAN-08-0161

186. Davidos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metast Rev 2010; 29:273-83; PMID:20390322; http://dx.doi.org/10.1007/s10555-010-9229-9

187. Lin H, Yan J, Wang Z, Hua F, Yu J, Sun W, Li K, Liu H, Yang H, Lv Q, et al. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatology 2013; 57:171-82; PMID:22859216; http://dx.doi.org/10.1002/hep.25991

188. Bretz JD, Mrozski E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ 2002; 9:274-86; PMID:11859410; http://dx.doi.org/10.1038/sj.cdd.4400965

189. Uno K, Inukai T, Kayagaki N, Got K, Sato I, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 2003; 101:3658-67; PMID:12506034; http://dx.doi.org/10.1182/blood-2002-06-1770

190. Song JH, Song DK, Pyrzynska B, Petruck KC, Van Meir EG, Hao C. TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003; 13:539-53; PMID:14655759; http://dx.doi.org/10.1111/j.1750-3639.2003.tb00484.x

191. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-37; PMID:15550937; http://dx.doi.org/10.1038/sj.cgt.7700792

192. Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol 2014; 20:9872-81; PMID:25110418; http://dx.doi.org/10.3748/wjg.v20.i29.9872

193. Kepp O, Tesniere A, Schlemmer F, Michaud M, Sukkurwala AQ, Adjemian S, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1574-7; PMID:21174253; http://dx.doi.org/10.1126/science.1208347

194. Michaud M, Martins I, Sakkurwala AQ, Adjemian S, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1574-7; PMID:21174253; http://dx.doi.org/10.1126/science.1208347

195. Ko A, Knebeisa A, Martin I, Sennovilla L, Chargari C, Dugue D, Marigo I, Kepp O, Mishaud M, Senovilla L, Zitvogel L, Kroemer G. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14:364-75; PMID:19145485; http://dx.doi.org/10.1007/s10495-008-0303-9

196. Rao S, Tortola L, Perlot T, Wernsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramm D, Komnenovic V, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5:3056; PMID:24445999; http://dx.doi.org/10.1038/ncomms4056

197. Dupont N, Lacas-Gervais S, Bertout J, Paz I, Freche B, Van Nhieu GT, van der Goot FG, Sansonnetti PJ, Lafont F. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. Cell Host Microbe 2009; 6:137-49; PMID:19683680; http://dx.doi.org/10.1016/j.chom.2009.07.005

198. Yang JQ, Liu H, Diaz-Meco MT, Moscat J. NBR1 is a new PB1 signaling adapter in Th2 differentiation and allergic airway inflammation in vivo. EMBO J 2010; 29:3421-33; PMID:20808283; http://dx.doi.org/10.1038/emboj.2010.214

199. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, Wilkins AD, Sun Q, Pallauf K, MacDuff D, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013; 494:201-6; PMID:23364696; http://dx.doi.org/10.1038/nature11866